A French research with a little test size and various other methodological shortcomings claimed that treatment with hydroxychloroquine increased the virus transformation towards the seronegative condition. has an revise over the used treatment, and intends to provide help in regards to daily treatment, without wanting to replace the protocols followed in every individual middle. Keywords:COVID-19, ARDS-CoV-2, Treatment, ICU == Abstract == La infeccin por un trojan SARS-CoV-2, denominada COVID-19 (COronaVIrus Disease 19), fue detectada inicialmente en China en diciembre 2019, con posteriormente se ha diseminado rpidamente por todo un mundo, hasta un punto de que un 11 de marzo la OMS declar que un brote podra definirse como pandemia. La COVID-19 presenta el cuadro que oscila desde episodios leves pseudogripales a otros graves e incluso potencialmente mortales debido, sobre todo, a insuficiencia respiratoria aguda. Ha sido frecuente un ingreso de estos pacientes en nuestros Servicios de Medicina Intensiva en relacin con el Sndrome de Distrs Respiratorio Agudo (SDRA). La falta de el tratamiento evidencia cientfica ha llevado al empleo de diferentes pautas teraputicas con, muchas ocasiones en, modificaciones rpidas de los protocolos con. Recientes revisiones en revistas de prestigio han destacado la falta de terapias probadas y la necesidad de ensayo clnicos que permitan establecer pautas de tratamiento claras y objetivas. Este documento tiene por objeto ofrecer una actualizacin de la terapia que se est aplicando en la actualidad, con una ayuda en la asistencia diaria, sin pretender sustituir los protocolos adoptados en cada centro. Palabras clave:COVID-19, SARS-CoV-2, Tratamiento, UCI == Launch == Infection because Isoorientin Isoorientin of SARS-CoV-2 trojan, the so-called COVID-19(COronaVIrus Disease 19), back Dec 2019 was discovered in China, 1and it pass on Isoorientin quickly across the world eventually, to the level that on March 11th the WHO announced this outbreak a worldwide pandemic.2In our country, the SEMICYUC has devised a Contingency Intend to arrange health care for critically ill patients with COVID-19.3SARS-CoV-2 causes clinical signals that go from light flu-like symptoms to serious as well as potentially dangerous episodes, especially, severe respiratory distress. These sufferers are often accepted to your Intensive Care Device with acute respiratory system distress symptoms (ARDS).4,5,6The insufficient cure backed with enough technological evidence has resulted in the usage of different therapeutic guidelines and quick modifications from the protocols. Latest review articles and editorials possess investigated the lack of proved therapies and have to carry out clinical studies to have the ability to create evidence-based scientific practice suggestions.7,8,9 The idea that COVID-19 disease undergoes several levels of progression continues to be suggested. The original stage will be characterized by a higher viral load; as a result, this would end up being the optimum time to manage effective antiviral therapies. In another stage, the inflammatory response is normally predominant (we’re able to even discuss a cytokine surprise symptoms) where anti-inflammatory medications play a significant function.10(Fig. 1). Nevertheless, we have not really been able to verify this theory however. == Fig. 1. == Progression of SARS-CoV-2 an infection. The arrangement is showed with the diagram from the span of SARS-CoV-2 infection as well Rabbit polyclonal to RB1 as the immune response measured by antibodies. Also, the next continues to be added: (A) Siddiqis and Mehras10proposal of scientific stages as well as the progression of adaptative immune system response mediated by antibody creation as well as the progression of the common viral an infection. Siddiqi and Mehra propose a scientific staging program in 3 different levels to facilitate the usage of a even nomenclature. Hence, they propose a stageior early an infection stage, a stageiior pulmonary stage, and a stageiiior hyperinflammatory stage with potential treatment in each stage together. However, that is somehow not the same as the bodys immune system response to viral an infection (B). Within this physical response to a viral an infection, the innate immune system response kicks in best at the start from the an infection before adaptative immune system response is made with the creation of antibodies just a couple days later. Hence, some medications utilized to take care of COVID-19 stop interleukin-1 that activates T interleukin-6 or cells that participates in B-cell maturation, the cells which will build the antibodies ultimately. To be able to.